19-Nov-2001 - Bayer AG

Bayer starts research collaboration with Italian biotech company in the field of post-genomics

Bayer's Italian research unit to be integrated into newly founded biotech company Axxam

Leverkusen – Bayer has entered a collaboration with Axxam S.r.l., a newly formed Italian biotechnology company, in the field of post-genomics with the objective of developing several technology platforms for modern drug discovery. The results of genome research are thus used to develop biological test systems. Bayer has agreed to integrate its Italian research unit – at the San Raffaele Biomedical Science Park in Milan – into Axxam. The objective of the agreement is to further increase and strengthen Bayer's activities in the drug discovery process.

By integrating its research group into the new company, Bayer will obtain a minority stake in Axxam's capital. Both companies have also signed a parallel five-year research deal valued at EUR 30 million, on the basis of which Axxam will develop for Bayer a new generation of highly advanced assay systems to be used at Bayer's UHTS (ultra-high-throughput screening) unit for drug discovery. The aim of this partnership is to build an ideal link between Bayer's excellent genomics platform and the lead identification program, which allows to test up to 200,000 compounds per day in a highly automated process. This collaboration probably represents the most important deal ever in the Italian biotech industry.

As Professor Wolfgang Hartwig, Head of Pharmaceutical Research at Bayer, pointed out, "The collaboration guarantees us continuing high-performance assay development, and in addition we can participate in the new scientific outcomes of Axxam at an early stage. The new company fits perfectly in our renowned technology platform strategy which gives Bayer access to leading technologies in the drug discovery process."

Dr. Stefan Lohmer, Chairman and Chief Executive Officer of Axxam, stated, "Modern biosciences hold an enormous potential for innovation which we can use in a very efficient and highly customized way. We can provide new ideas and excellent technologies in the fields of genomics and assay development which will significantly accelerate the drug discovery process. We are delighted to be part of Bayer's well-known and reputable drug discovery platform."

Axxam is a technology-oriented research biotech company with leading expertise, know-how and cutting-edge technologies for target validation and for development of advanced screening assay systems (UHTS format). The company is located at the prestigious San Raffaele Biomedical Science Park in Milan, one of the largest and most advanced Italian biomedical and biotechnological research institutes. The personnel comprises 40 research scientists and laboratory technicians who already have experience in the field, but an increase to the head count and instrumentation and technology capacity is expected in the next few years. The company's management team comprises the two co-founders, Dr. Stefan Lohmer, Chairman and Chief Executive Officer, formerly Head of the Bayer Research Unit at San Raffaele and formerly Head of Bayer's international genomic research, and Dr. Alessandro Sidoli, Chief Operating Officer, formerly Head of Biotechnology Transfer at San Raffaele and founder of Primm, an Italian biotechnology company started in 1990 and one of Italy's successful examples of biotech start-ups.

Facts, background information, dossiers
  • Bayer
  • Axxam
  • genomics
More about Bayer
  • News

    Bayer strategically and operationally successful

    Bayer was strategically and operationally successful last year. “We delivered in 2019 and kept our promises in all areas,” Werner Baumann, Chairman of the Board of Management, said on Thursday at the Financial News Conference in Leverkusen. “We achieved our financial targets despite coming ... more

    Norbert Winkeljohann to succeed Werner Wenning as Chairman of Bayer’s Supervisory Board

    Prof. Dr. Norbert Winkeljohann, 62, is to become Chairman of the Supervisory Board of Bayer AG. As decided at Supervisory Board meeting, Winkeljohann will succeed Werner Wenning, 73, who is to step down with effect from the end of the Annual Stockholders’ Meeting on April 28, 2020. Winkeljo ... more

    Bayer completes sale of Currenta stake

    Bayer has completed the sale of its 60 percent stake in chemical park operator Currenta to funds managed by Macquarie Infrastructure and Real Assets (MIRA). The two companies had entered into an agreement to this effect back in August. The closing conditions, including approval by the respo ... more

  • Companies

    Bayer Technology Services México

    Bayer Technology Services stands for technological competence throughout the service life of processes or units. We support our customers from the development of innovative products and processes to engineering and construction of units, to operating control and optimization – with courage, ... more

    Bayer Corporation

    Bayer Corporation, headquartered in Pittsburgh, is a subsidiary of Bayer AG, an international health care, nutrition and innovative materials group based in Leverkusen, Germany. In North America, Bayer had 2006 net sales of 7.8 billion euros and employed 17,200 at year end. Bayer’s three s ... more

    Bayer S.A./NV.

    Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and high earni ... more